Back to Peptide Library

GHK (Glycyl-L-Histidyl-L-Lysine)

glycyl-L-histidyl-L-lysine

Early-Stage ClinicalInvestigationalPrimary Endpoint Met

Early clinical trials have shown positive signals, but larger trials are needed to confirm benefits and safety.

A natural compound in the human body that decreases with age and shows evidence for promoting skin regeneration and wound healing, especially when bound to copper (as GHK-Cu). Research suggests it may help aging tissue function more like younger tissue, and it is widely used in cosmetic anti-aging products.

11 studiesUpdated 2026-03-10Topical · Subcutaneous

This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.

Clinical bottom lineMixed evidence

GHK (Glycyl-L-Histidyl-L-Lysine) has moderate clinical evidence but is not FDA-approved.

Early clinical trials have shown positive signals, but larger trials are needed to confirm benefits and safety.

Safety Summary

Topical GHK-Cu has a safety record built on decades of cosmeceutical use. A safety review analyzed 12 studies (n=512) and reported transient erythema in 4.2% and pruritus in 2.8% of subjects, with no systemic effects consistently reported. Plasma copper levels remained unchanged in monitored trials. A post-marketing surveillance dataset (n=1,200 users) reported <1% contact dermatitis. Formal approved-label safety language and FAERS case signals were not found in the available corpus. GHK is a naturally occurring endogenous human peptide, contributing to its favorable tolerability. No documented cases of systemic toxicity from topical use in published literature. Important caveat: the specific safety review statistics (4.2%, 2.8%, n=512, n=1,200) come from a commercial vendor source, and the specific PMIDs cited by that source could not be independently verified in the downloaded papers. Community discussion mentions red and painful subcutaneous injection sites, but this remains anecdotal self-experimentation.

Clinical check-in

If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.

See cited studies on this page (11)

Cited sources

Every claim on this page links to one of the 11 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.

  1. 1PMID 26236730PubMed
  2. 2PMID 15931022PubMed
  3. 3PMID 22372789PubMed
  4. 4PMID 22585766PubMed
  5. 5PMID 10485305PubMed
  6. 6PMID 24704744PubMed
  7. 7PMID 30002421PubMed
  8. 8PMID 10689625PubMed
  9. 9NCT07437586ClinicalTrials.gov
  10. 10NCT05932732ClinicalTrials.gov
  11. 11PMID 41771428PubMed